Prashanth Ashok Kumar
Hematology & Oncology · Washington, DCNPI 1245726371
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.4% of the total across 10 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by AstraZeneca at 36.1% of the total. That places this record below the midpoint for hematology & oncology clinicians in DC, where the typical reported total is $4,025.
Across 10 payments — averaging $26.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$97
- Merck$57
- Daiichi Sankyo Inc.$42
- Coherus Oncology, Inc.$31
- Penumbra, Inc.$21
- Genentech USA, Inc.$21
What the payments were for
- Food & beverage$24490%
- Education$2610%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 3 | $97 |
| Merck | 2 | $57 |
| Daiichi Sankyo Inc. | 2 | $42 |
| Coherus Oncology, Inc. | 1 | $31 |
| Penumbra, Inc. | 1 | $21 |
| Genentech USA, Inc. | 1 | $21 |
How this compares
$269 in reported general payments places this provider in the 25th percentile of 69 hematology & oncology providers in District of Columbia.
See all hematology & oncology providers in District of Columbia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Abiraterone Acetate | 12 | $3,203 |
| Prochlorperazine Maleate | 12 | $119 |
| Ondansetron Hcl | 18 | $92 |
| Prednisone | 23 | $85 |
| Dexamethasone | 13 | $50 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Washington
- Imadeddine TabbaraWashington$1.2M
- John MarshallWashington$525K
- Catherine BroomeWashington$504K
- Craig KesslerWashington$449K
- Benjamin WeinbergWashington$326K
- Claudine IsaacsWashington$241K
- Chul KimWashington$173K
- Christopher GallagherWashington$109K
- Neil ShahWashington$76K
- Vered StearnsWashington$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.